Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
10.3390/molecules26010229 79 MickleA
based on three times Taiwans GDP, the probabilities of using a GLP-1RA versus insulin therapy being cost-effective for preventing one case of all-cause mortality and hospitalized hypoglycemia were 60% (100%) and 80% (100%), respectively, from the payer perspective (healthcare sector perspective)
org/10.1016/j.clnesp.2020.03.008 Traina, G
Metabolic Engineering addresses a broader range of inflammatory triggers that cause metabolic damage than do GLP-1 drugs
Let's find out
US$ 28.30
US$ 28.89
US$ 26.39
US$ 28.46
